|
Gene: MTOR |
Gene summary for MTOR |
Gene summary. |
Gene information | Species | Human | Gene symbol | MTOR | Gene ID | 2475 |
Gene name | mechanistic target of rapamycin kinase | |
Gene Alias | FRAP | |
Cytomap | 1p36.22 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P42345 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2475 | MTOR | LZE4T | Human | Esophagus | ESCC | 5.59e-03 | 1.11e-01 | 0.0811 |
2475 | MTOR | LZE7T | Human | Esophagus | ESCC | 1.14e-07 | 3.37e-01 | 0.0667 |
2475 | MTOR | LZE22T | Human | Esophagus | ESCC | 5.81e-05 | 2.77e-01 | 0.068 |
2475 | MTOR | LZE24T | Human | Esophagus | ESCC | 2.01e-06 | 1.95e-01 | 0.0596 |
2475 | MTOR | P1T-E | Human | Esophagus | ESCC | 9.72e-03 | 1.92e-01 | 0.0875 |
2475 | MTOR | P2T-E | Human | Esophagus | ESCC | 8.23e-15 | 2.40e-01 | 0.1177 |
2475 | MTOR | P4T-E | Human | Esophagus | ESCC | 1.45e-03 | 1.53e-01 | 0.1323 |
2475 | MTOR | P5T-E | Human | Esophagus | ESCC | 1.05e-05 | 1.06e-01 | 0.1327 |
2475 | MTOR | P8T-E | Human | Esophagus | ESCC | 5.70e-08 | 1.83e-01 | 0.0889 |
2475 | MTOR | P9T-E | Human | Esophagus | ESCC | 1.17e-07 | 1.58e-01 | 0.1131 |
2475 | MTOR | P10T-E | Human | Esophagus | ESCC | 1.02e-11 | 3.18e-01 | 0.116 |
2475 | MTOR | P11T-E | Human | Esophagus | ESCC | 1.64e-03 | 2.21e-01 | 0.1426 |
2475 | MTOR | P12T-E | Human | Esophagus | ESCC | 2.79e-05 | 1.63e-01 | 0.1122 |
2475 | MTOR | P15T-E | Human | Esophagus | ESCC | 1.78e-16 | 3.60e-01 | 0.1149 |
2475 | MTOR | P16T-E | Human | Esophagus | ESCC | 5.11e-04 | 1.50e-01 | 0.1153 |
2475 | MTOR | P17T-E | Human | Esophagus | ESCC | 3.33e-07 | 3.42e-01 | 0.1278 |
2475 | MTOR | P19T-E | Human | Esophagus | ESCC | 4.16e-05 | 3.45e-01 | 0.1662 |
2475 | MTOR | P20T-E | Human | Esophagus | ESCC | 4.86e-10 | 2.31e-01 | 0.1124 |
2475 | MTOR | P21T-E | Human | Esophagus | ESCC | 1.81e-22 | 4.41e-01 | 0.1617 |
2475 | MTOR | P22T-E | Human | Esophagus | ESCC | 2.19e-12 | 1.39e-01 | 0.1236 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016678 | Breast | Precancer | ameboidal-type cell migration | 47/1080 | 475/18723 | 2.19e-04 | 3.35e-03 | 47 |
GO:00160497 | Breast | Precancer | cell growth | 46/1080 | 482/18723 | 5.63e-04 | 7.16e-03 | 46 |
GO:00192164 | Breast | Precancer | regulation of lipid metabolic process | 34/1080 | 331/18723 | 8.14e-04 | 9.55e-03 | 34 |
GO:00015587 | Breast | Precancer | regulation of cell growth | 39/1080 | 414/18723 | 1.81e-03 | 1.78e-02 | 39 |
GO:00011015 | Breast | Precancer | response to acid chemical | 16/1080 | 135/18723 | 4.85e-03 | 3.67e-02 | 16 |
GO:01501158 | Breast | Precancer | cell-substrate junction organization | 13/1080 | 101/18723 | 5.30e-03 | 3.94e-02 | 13 |
GO:01501168 | Breast | Precancer | regulation of cell-substrate junction organization | 10/1080 | 71/18723 | 7.33e-03 | 4.88e-02 | 10 |
GO:000166714 | Breast | IDC | ameboidal-type cell migration | 64/1434 | 475/18723 | 6.65e-06 | 2.05e-04 | 64 |
GO:001921612 | Breast | IDC | regulation of lipid metabolic process | 45/1434 | 331/18723 | 1.21e-04 | 2.24e-03 | 45 |
GO:00192184 | Breast | IDC | regulation of steroid metabolic process | 18/1434 | 100/18723 | 5.40e-04 | 6.96e-03 | 18 |
GO:001604913 | Breast | IDC | cell growth | 56/1434 | 482/18723 | 1.16e-03 | 1.26e-02 | 56 |
GO:000155813 | Breast | IDC | regulation of cell growth | 49/1434 | 414/18723 | 1.55e-03 | 1.55e-02 | 49 |
GO:000110112 | Breast | IDC | response to acid chemical | 20/1434 | 135/18723 | 3.28e-03 | 2.75e-02 | 20 |
GO:00431126 | Breast | IDC | receptor metabolic process | 23/1434 | 166/18723 | 4.04e-03 | 3.25e-02 | 23 |
GO:00432003 | Breast | IDC | response to amino acid | 17/1434 | 116/18723 | 7.13e-03 | 4.92e-02 | 17 |
GO:000166723 | Breast | DCIS | ameboidal-type cell migration | 62/1390 | 475/18723 | 9.60e-06 | 2.56e-04 | 62 |
GO:001921621 | Breast | DCIS | regulation of lipid metabolic process | 43/1390 | 331/18723 | 2.37e-04 | 3.71e-03 | 43 |
GO:001604923 | Breast | DCIS | cell growth | 54/1390 | 482/18723 | 1.60e-03 | 1.59e-02 | 54 |
GO:000155822 | Breast | DCIS | regulation of cell growth | 47/1390 | 414/18723 | 2.39e-03 | 2.16e-02 | 47 |
GO:004311213 | Breast | DCIS | receptor metabolic process | 23/1390 | 166/18723 | 2.75e-03 | 2.41e-02 | 23 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0521216 | Esophagus | ESCC | Pancreatic cancer | 62/4205 | 76/8465 | 7.37e-09 | 6.85e-08 | 3.51e-08 | 62 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0406629 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
hsa0501728 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTOR | SNV | Missense_Mutation | novel | c.4688G>A | p.Cys1563Tyr | p.C1563Y | P42345 | protein_coding | tolerated(1) | benign(0.284) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MTOR | SNV | Missense_Mutation | rs780930764 | c.4439G>A | p.Arg1480His | p.R1480H | P42345 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MTOR | SNV | Missense_Mutation | novel | c.4171C>G | p.Arg1391Gly | p.R1391G | P42345 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MTOR | SNV | Missense_Mutation | c.6644C>A | p.Ser2215Tyr | p.S2215Y | P42345 | protein_coding | deleterious(0) | possibly_damaging(0.876) | TCGA-AX-A1CJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MTOR | SNV | Missense_Mutation | rs752458445 | c.6454C>T | p.Arg2152Cys | p.R2152C | P42345 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
MTOR | SNV | Missense_Mutation | c.2656C>A | p.Arg886Ser | p.R886S | P42345 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
MTOR | SNV | Missense_Mutation | rs763230714 | c.308G>A | p.Arg103Gln | p.R103Q | P42345 | protein_coding | tolerated(0.14) | benign(0.006) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
MTOR | SNV | Missense_Mutation | novel | c.4209G>T | p.Glu1403Asp | p.E1403D | P42345 | protein_coding | deleterious(0.02) | probably_damaging(0.931) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | novel | c.541A>G | p.Thr181Ala | p.T181A | P42345 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MTOR | SNV | Missense_Mutation | rs752641006 | c.6809N>A | p.Arg2270Gln | p.R2270Q | P42345 | protein_coding | tolerated(1) | benign(0.081) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | QUINACRINE | QUINACRINE | ||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | BEZ235 | DACTOLISIB | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | TCMDC-125575 | CHEMBL587620 | ||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | PERPHENAZINE | PERPHENAZINE | ||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | PAZOPANIB | PAZOPANIB | 24625776 | |
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | inhibitor | 249565693 | ||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | CAFFEIC ACID PHENETHYL ESTER | CAFFEIC ACID PHENETHYL ESTER | ||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | AZD2014 | VISTUSERTIB | ||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | GDC-0980/RG7422 | |||
2475 | MTOR | DRUG RESISTANCE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE, ENZYME | EVEROLIMUS | EVEROLIMUS | 24625776,25295501 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |